FGF-2 and Anosmin-1 Are Selectively Expressed in Different Types of Multiple Sclerosis Lesions
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is a demyelinating disease that affects ∼2,000,000 people worldwide. In the advanced stages of the disease, endogenous oligodendrocyte precursors cannot colonize the lesions or differentiate into myelinating oligodendrocytes. During development, both FGF-2 and Anosmin-1 participate in oligodendrocyte precursor cell migration, acting via the FGF receptor 1 (FGFR1). Hence, we performed a histopathological and molecular analysis of these developmental modulators in postmortem tissue blocks from multiple sclerosis patients. Accordingly, we demonstrate that the distribution of FGF-2 and Anosmin-1 varies between the different types of multiple sclerosis lesions: FGF-2 is expressed only within active lesions and in the periplaque of chronic lesions, whereas Anosmin-1 is upregulated within chronic lesions and is totally absent in active lesions. We show that the endogenous oligodendrocyte precursor cells recruited toward chronic-active lesions express FGFR1, possibly in response to the FGF-2 produced by microglial cells in the periplaque. Also in human tissue, FGF-2 is upregulated in perivascular astrocytes in regions of the normal-appearing gray matter, where the integrity of the blood–brain barrier is compromised. In culture, FGF-2 and Anosmin-1 influence adult mouse oligodendrocyte precursor cell migration in the same manner as at embryonic stages, providing an explanation for the histopathological observations: FGF-2 attracts/enhances its migration, which is hindered by Anosmin-1. We propose that FGF-2 and Anosmin-1 are markers for the histopathological type and the level of inflammation of multiple sclerosis lesions, and that they may serve as novel pharmacogenetic targets to design future therapies that favor effective remyelination and protect the blood–brain barrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 1×
“Plaques present in brain tissue samples from 10 human MS patients were classified (Table 1) according to previously described methods (Trapp et al., 1999; Chang et al., 2002, 2008; Benito et al., 2007; Koning et al., 2007; Breij et al., 2008; Young et al., 2008).”
MethodHyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 2×
“, 2010), and is similar to that previously demonstrated for other molecules involved in OPC migration (Back et al., 2005; Omari et al., 2005; Williams et al., 2007; Wang et al., 2008).”
ResultbHLH Transcription Factor Olig1 Is Required to Repair Demyelinated Lesions in the CNS
Arnett, H. A., Fancy, S. P. J., Alberta, J. A., Zhao, C., Plant, S. R., Kaing, S., Raine, C. S., Rowitch, D. H., Franklin, R. J. M., & Stiles, C. D. (2004) · Science · doi:10.1126/science.1103709 · Cited by 416
Kotter, M. R., Setzu, A., Sim, F. J., Van Rooijen, N., & Franklin, R. J. M. (2001) · Glia · doi:10.1002/glia.1085 · Cited by 385 · cited 1×
“…has been postulated that myelination may be facilitated in active lesions by inflammation and infiltrating (or microglial-derived) macrophages, which provide the tissue with growth factors (Diemel et al., 1998; Kotter et al., 2001) and/or cues, such as secreted semaphorins (Williams et al., 2007).”
BackgroundBenito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., & Romero, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-06.2007 · Cited by 256
Self-citationArmstrong, R. C., Le, T. Q., Frost, E. E., Borke, R. C., & Vana, A. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08574.2002 · Cited by 178 · cited 1×
“However, considering the data from mouse models of demyelination, an elevated amount of FGF-2 within active lesions not only appears to favor the recruitment of FGFR1 OPCs but also to inhibit their differentiation toward myelinating oligodendrocytes (Armstrong et al., 2002, 2006).”
BackgroundRegulation of FGF receptors in the oligodendrocyte lineage
Bansal, R., Kumar, M., Murray, K., Morrison, R. S., & Pfeiffer, S. E. (1996) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1996.0020 · Cited by 160
Endogenous cell repair of chronic demyelination
Armstrong, R. C., Le, T. Q., Flint, N. C., Vana, A. C., & Zhou, Y.-X. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000205142.08716.7e · Cited by 125
Macrophages in CNS remyelination: friend or foe?
Diemel, L. T., Copelman, C. A., & Cuzner, M. L. (1998) · Neurochemical Research · doi:10.1023/a:1022405516630 · Cited by 78 · cited 2×
“It has been postulated that myelination may be facilitated in active lesions by inflammation and infiltrating (or microglial-derived) macrophages, which provide the tissue with growth factors (Diemel et al., 1998; Kotter et al., 2001) and/or cues, such as secreted semaphorins (Williams et al.”
Background
Cited by
Xing, Y. L., Röth, P. T., Stratton, J. A. S., Chuang, B. H. A., Danne, J., Ellis, S. L., Ng, S. W., Kilpatrick, T. J., & Merson, T. D. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3491-13.2014 · Cited by 275
“Levels of both FGF-2 and PDGF-AA are elevated in the brain tissue of humans with MS (Clemente et al., 2011) and in the cuprizone model (Gudi et al.”
BackgroundFibroblast Growth Factor-2 Signaling in Neurogenesis and Neurodegeneration
Woodbury, M. E., & Ikezu, T. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9501-5 · Cited by 266
“Moreover, in postmortem MS human brain tissue, FGF2 is expressed in microglia and macrophages in active lesions (lesions exhibiting signs of remyelination), and oligodendrocyte precursor cells recruited to these lesions express FGFR1(Clemente et al. 2011).”
Dietary cholesterol promotes repair of demyelinated lesions in the adult brain
Berghoff, S. A., Gerndt, N., Winchenbach, J., Stumpf, S. K., Hosang, L., Odoardi, F., Ruhwedel, T., Böhler, C., Barrette, B., Stassart, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14241 · Cited by 151
Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis
Tejera-Alhambra, M., Casrouge, A., de Andrés, C., Seyfferth, A., Ramos-Medina, R., Alonso, B., Vega, J., Fernández-Paredes, L., Albert, M. L., & Sánchez-Ramón, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128952 · Cited by 55
Metadata
- Authors
- Clemente, D., Ortega, M. C., Arenzana, F. J., & de Castro, F.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2011-10-19
- Volume
- 31
- Issue
- 42
- Pages
- 14899-14909
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1974656309
- Cited by
- 124
- References
- 9
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FGF-2 and Anosmin-1 Are Selectively Expressed in Different Types of Multiple Sclerosis Lesions. https://app.cochat.ai/papers/10.1523/jneurosci.1158-11.2011
- The paper
- Clemente, D., Ortega, M. C., Arenzana, F. J., & de Castro, F. (2011). FGF-2 and Anosmin-1 Are Selectively Expressed in Different Types of Multiple Sclerosis Lesions. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1158-11.2011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.